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Abstract 
Non-alcoholic fatty liver disease (NAFLD) can progress from ‘simple steatosis’ (NAFL) to non-alcoholic 
steatohepatitis (NASH), cirrhosis and cancer. Currently the driver for this progression is not fully 
understood; in particular it is not known how NAFLD and its early progression affects the distribution 
of lipids in the liver, producing lipotoxicity and inflammation. Here we use dietary and genetic mouse 
models of NAFL and NASH, and translate results to humans, by correlating the spatial distribution of 
lipids in liver tissue with disease progression, using advanced mass spectrometry imaging technology. 
We identified several lipids with distinct zonal distributions in control and NAFL samples, whilst partial 
to complete loss of lipid zonation was found in NASH. In addition, we found increased hepatic 
expression of genes associated with remodelling the phospholipid membrane, release of arachidonic 
acid (AA) from the membrane, and production of eicosanoid species which promote inflammation and 
cell injury. Using immunohistochemistry, we further suggest that the zonal location of remodelling 
enzyme lysophosphatidylcholine acyl transferase 2 (LPCAT2) plays a role in the change in spatial 
distribution for arachidonic acid (AA)-containing lipids. This results in a cycle of AA-enrichment in 
pericentral hepatocytes, membrane release of AA and generation of pro-inflammatory eicosanoids, 
and may account for increased oxidative damage in pericentral regions in NASH. Conclusion: We have 
demonstrated that NAFLD is associated not only with lipid enrichment, but also to zonal changes of 
specific lipids and their associated metabolic pathways. This may play a role in the heterogeneous 
development of NAFLD.  
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Introduction 
Non-alcoholic fatty liver disease (NAFLD) is characterised by accumulation of triacylglycerides (TAG) in 
the liver (steatosis); however a subgroup of patients will progress to more serious conditions, including 
non-alcoholic steatohepatitis (NASH), cirrhosis, hepatocarcinoma and liver failure (1-4). A ‘multiple-
hit’ process for NAFLD has been suggested, whereby fatty liver is followed by oxidative stress and lipid 
peroxidation leading to an inflammation cascade, cell injury and the development of NASH (5). 
However, the detailed mechanisms underlying disease progression remain poorly understood.   
 
Given that NAFLD is characterised by an imbalance in lipid homeostasis, lipidomics approaches are 
well placed to interrogate the specific changes associated with this disease (6). Previous studies have 
concentrated on discovering biomarkers to differentiate between ‘healthy’ fatty liver (NAFL) and 
NASH (7-9), and to establish changes to the lipidome with progression of NAFLD (10, 11). However, 
many of these previous studies have focussed on circulating markers for liver disease, and hence are 
distal to the actual pathophysiology, or rely on tissue extracts that ignore the heterogeneous nature 
of the disease.  
 
Different zones exist in the liver lobules according to proximity to the portal triad - the main supplier 
of nutrient and oxygen-rich blood to the liver. In addition to a gradient of nutrients and oxygen, 
zonation of glucose and fatty acid metabolism has been observed (12). Whilst hepatocytes closest to 
the portal vein (periportal or zone 1) are more involved in gluconeogenesis and -oxidation of fatty 
acids, glycolysis and lipogenesis occur at a higher rate in hepatocytes closest to the central vein 
(pericentral or zone 3) (12). Furthermore, steatosis in adult NAFL and oxidative damage to cells in 
NASH are chiefly localised to pericentral regions (1). As a consequence, lipids are distributed 
differentially within the liver lobule; however, little is known on how the development and progression 
of NAFLD affects lipid zonation and metabolism. Proof-of-principle studies have shown that mass 
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spectrometry imaging (MSI), a transformative technology enabling the in situ analysis of tissue 
molecular composition (13-15), can detect the differential distribution of lipids in both healthy and 
steatotic liver tissue (16-18).  
 
Here we study dietary and genetic models of NAFL and NASH in mice to complement a set of human 
liver biopsies. Using matrix assisted laser desorption ionisation (MALDI) MSI, coupled with lipidomics 
techniques and bioinformatics tools, we monitored subtle changes in the distribution and abundance 
of lipids as a function of their location within the liver lobule. We found several lipids with distinct 
distributions in control and NAFL liver, along with an increase in pro-inflammatory arachidonic acid 
(AA)-derived lipoxygenase (LOX) metabolites. Progression to NASH however, led to increasing loss of 
lipid zonation. 
 
We further found increased hepatic mRNA levels in both mouse and human NAFLD samples for genes 
associated with membrane remodelling (LPCAT2, cPLA2) and eicosanoid production (ALOX15). 
Additionally, immunostaining revealed that lysophosphatidylcholine acyl transferase 2 protein 
(LPCAT2), which is responsible for incorporation of AA into the membrane, had a distinct pericentral 
distribution in human liver. Upregulation of LPCAT2 in NAFLD may therefore be a potential driving 
force behind enrichment of AA in pericentral hepatocytes, enabling the phospholipid membrane to 
serve as a substrate pool for free AA and its eicosanoid metabolites. This study is the first to suggest 
the potential importance of the physical location of intact lipids and their associated metabolic 
pathways in the pathology of NAFLD.  
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Experimental Procedures 
Mouse samples 
High fat diet: Five-week old male ob/ob (N=5) and wild type (WT, C57BL/6J strain, N=5) mice were 
maintained on a high fat diet or regular chow diet for 12 weeks. High fat diet caloric content was 55% 
fat, 29% protein, 16% carbohydrate (diet code: 829197; Special Diet Services, UK). Regular chow diet 
caloric content was 11.5% fat, 26.9% protein, 61.6% carbohydrate (RM1; Special Diet Services, UK). 
Western diet: Eight-week old male WT (C57BL/6J strain) mice were maintained on a western diet 
(N=5/time point; adjusted calories diet code: TD.88137; caloric content: 42.0 % fat, 15.2 % protein, 
42.7 % carbohydrate, 0.2 % cholesterol; Harlan Laboratories, Madison) or low fat control diet 
(N=5/time point; TD 08485; caloric content: 13 % fat, 19.2% protein, 67.9 % carbohydrate; Harlan 
Laboratories, Madison) for 12 or 32 weeks. 
Methionine choline deficient diet: Eight-week old male WT mice (FVB/N strain) were fed MCD high-fat 
diet (N=5; D12451, Research Diets) or MCS control diet (N=5) for 8 weeks as described previously (19). 
Mice were euthanized, and the liver tissue rapidly dissected and snap-frozen. Liver enzyme activity 
assays were performed on collected serum. All animal protocols were approved by the UK Home 
Office and the University of Cambridge Animal Welfare and Ethical Review Board, and carried out by 
a personal licence holder. 
 
Human samples 
Twenty-three human samples were obtained from the Human Research Tissue Bank, at 
Addenbrooke’s Hospital, Cambridge (Cambridgeshire 2 Research Ethics Committee, NRES 
11/EE/0011). Samples were scored contemporaneously by an experienced histopathologist for 
steatosis (0-3), ballooning (0-2), inflammation (0-2), fibrosis (0-4) and were diagnosed according to the 
SAF system (20). Samples were thus classified as normal (N=2), NAFL (N=11), borderline minimal NASH 
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(N=4), moderate NASH (N=5) and cirrhosis (N=1). All samples were analysed, but for the purposes of 
statistics, comparisons were made between two groups: NAFL (N=11) and borderline NASH/NASH 
(N=9), hereafter referred to as NASH.  
 
MALDI Imaging MS 
Mouse and human liver samples were embedded in Tissue-Tek® OCT™ and 10 m frozen sections on 
glass microscope slides were prepared using a cryostat. Adjacent sections were stained with 
haematoxylin and eosin (H&E) or Masson’s trichrome. Tissue sections were washed with 50 mM 
potassium nitrate (5 s) prior to matrix application in order to form exclusively potassiated adducts 
(Figure S1A) to reduce spectral complexity (a combination of K+, Na+ and H+ adducts are normally 
detected with MALDI). Matrix solutions (10 mg/mL) of 2, 5-dihydroxybenzoic acid (DHB; Sigma-Aldrich, 
St Louis, MO) were prepared in 85:15 methanol: water (v/v) and administered to the tissue surface 
using a nebulised sprayer (Suncollect MALDI spotter, KR Analytical Ltd, Cheshire, UK). Imaging 
experiments were carried out for three biological replicates per group (mouse) and all human samples 
using a MALDI LTQ Orbitrap XL (Thermo Fisher Scientific) at 50 m step increments across the tissue. 
Spectra were acquired in positive ion mode, from 250-1000 m/z at 60,000 resolution. Lipid identity 
was performed by accurate mass using the LipidMaps database (21). The predominant fatty acid 
composition was confirmed where possible by tandem MS using collision-induced dissociation (CID). 
In order to improve fragmentation, lithium adducts with more efficient fragmentation (22) were 
formed by a 5 s washing step in lithium nitrate (50 mM) prior to deposition of matrix, and the 
corresponding lithiated ions subjected to fragmentation (Figure S1B).   
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Lipidomics 
Lipids were extracted using an adaptation of the Folch method (23). Briefly, 400 L of deionised water 
was added to 30 mg of liver tissue and homogenised using a TissueLyser (Qiagen Ltd., Manchester, 
UK). Chloroform: methanol (2:1, 1 mL) was added and the samples vortexed and centrifuged (12,000 
g, 10 min). The extraction was performed twice, and the resulting organic layers were combined, dried 
under nitrogen and reconstituted in chloroform: methanol (2:1, 300 µL). Prior to analysis, samples (20 
L) were diluted in isopropanol: acetonitrile: water (2: 1: 1, 980 µL).  
 
Samples were analysed by liquid chromatography-mass spectrometry (LC-MS) using an Accela 
Autosampler (Thermo Scientific, Hemel Hempstead, UK) coupled to a LTQ Orbitrap EliteTM (Thermo 
Scientific). Five L of sample was injected onto an Acuity C18 BEH column (Waters Ltd., Warrington, 
UK;  50 × 2.1 mm, 1.7 µm) maintained at 55 C. Mobile phase A was 100 mM ammonium formate in 
acetonitrile: water 60:40 and mobile phase B was 100 mM ammonium formate in  isopropanol: 
acetonitrile 90:10 . The flow rate was 0.5 mL/min; the mobile phase gradient is detailed in Table S1. A 
heated electrospray ionisation source was maintained at 375 ˚ C, the desolvation temperature was 380 
˚C and desolvation gas flow at 40 arbitrary units. Spectra were acquired in positive and negative ion 
mode in the range of 100 - 2000 m/z.  
 
Gas chromatography-mass spectrometry 
Liver tissue or pellets of feed were extracted as described above. Total fatty acids in the dried lipid 
extract (200 µL) were derivatized using methanolic boron trifluoride (14 %, 125 µL). Chloroform: 
methanol (1:1, 100 µL) was added, and the samples heated to 80 °C for 90 mins. After cooling, 
deionised water (300 L) and hexane (600 L) were added to each sample. The upper organic fractions 
were separated, dried under nitrogen and reconstituted in hexane (200 L) for analysis.  
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A 7683 series autosampler (Agilent Technologies, Santa Clara, CA, USA) coupled to a 7683B Injector 
(Agilent Technologies, Santa Clara, CA, USA) was used to inject 1 L of sample onto an HP88 GC column 
(Agilent Technologies) (88% - cyanopropyl aryl-polysiloxane, 0.17 m thickness, 320 m diameter, 50 
m length). The injector temperature was 250 °C using a split ratio of 10:1, and flow rate of helium was 
12 mL/min. An initial temperature of 100 °C was held for 1 min, followed by a temperature ramp of 
10 °C/min to 300 °C, maintained for 2 min. Data were acquired after a solvent delay of 4 min (60 - 400 
m/z). 
 
Eicosanoid assay 
Eicosanoids were extracted from homogenised tissue (50 mg) as described previously (24). Samples 
were analysed by LC-MS/MS on a 5500 QTRAP (ABSciex UK Limited, Warrington, UK) coupled to an 
ACQUITY system (Waters Ltd., Warrington, UK). Samples were injected (10 L) onto a Kinetex 2.6 µm 
XB-C18 100 Å column (100 x 2.1 mm, Phenomenex, Macclesfield, UK) at 30 °C. Mobile phase A 
consisted of 0.1 % acetic acid in water, whilst mobile phase B was 0.1 % acetic acid in 80:20 
acetonitrile: methanol (0.5 mL/min, gradient in Table S2). The electrospray source was operated in 
negative ion mode (4.5 kV and 650 °C). Mass transitions of 51 analytes and 3 isotopically labelled 
standards (Table S3) were acquired. Peaks were integrated within Analyst™ version 1.6 and 
normalised against wet tissue weight and isotopically labelled internal standard; quantification was 
performed using available standards (Cayman Chemical Company).  
 
Transcript quantification  
Total RNA was purified from frozen human and mouse liver using a RNeasy Mini Kit (Qiagen). Briefly, 
approximately 20 mg tissue samples were lysed and homogenised in Trizol (1 mL) using a TissueLyzer 
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(Qiagen). The samples were centrifuged at 12,000 g for 15 min following the addition of chloroform 
(200 µL) and the RNA-containing aqueous phase combined with 1 volume of 70 % ethanol. Samples 
were loaded on spin columns and procedure continued as per the manufacturer guidelines. Purified 
RNA concentration was quantified (260 nm) using a NanoDrop 100 (Thermo Fisher Scientific). Genomic 
DNA contamination was eliminated using RT2 First Strand Kit (Qiagen) and complimentary DNA 
produced using RT2 First Strand Kit (Qiagen). Relative abundance of transcripts of interest was 
assessed by quantitative-PCR in RT2 SYBRgreen Mastermix (Qiagen) with a StepOnePlus detection 
system (Applied Biosciences, Warrington, UK). RT2 primer assays for mouse Rn18s (endogenous 
control), cPla2, Lpcat2, Alox5, Alox12, Alox15, Tnf-, Tgb-1 and human ACTB (endogenous control), 
cPLA2, LPCAT2 and ALOX15 were obtained from Qiagen. Thermocycler (PTC-200, MJ Research) 
parameters were: incubation, 95 °C for 10 min; elongation, 95 °C for 15 s; and cooling, 60 °C for 1 min. 
Elongation and cooling underwent 40 cycles. Expression levels were normalised to endogenous 
controls using the ∆∆CT method.  
 
Immunohistochemistry 
Immunostaining was performed on 10 μm frozen sections, fixed in cold acetone using the Rabbit 
VECTASTAIN ELITE ABC horseradish peroxidase kit (Vector Laboratories Ltd, Peterborough, UK) 
following the manufacturer’s protocol. Counter-staining was performed using haematoxylin (Sigma-
Aldrich). Primary antibodies were anti-LPCAT2 (Atlas Antibodies, Stockholm, Sweden; HPA007891; 
1:200 (mouse) 1:500 (human)) and anti-CD68 (Abcam, Cambridge, UK; ab955; 1:250). 
 
Data processing 
Lipidomics: Data were converted to mzML format for subsequent data processing, and features were 
picked using an in-house R script. Principal components analysis (PCA) and orthogonal projection to 
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latent structures discriminant analysis (OPLS-DA) models (25, 26) were constructed using SIMCA 14 
(Umetrics, Sweden), following normalisation to the total ion count, and Pareto scaling (27).  
 
MALDI-MSI: Each MALDI-MSI experiment is composed of multidimensional data, whereby every pixel 
(x, y coordinate) is associated with a mass spectrum (m/z, intensities). Data from MALDI-MSI were 
converted to imzML format for processing (28). Using an in-house R script, ions were retained above 
a threshold intensity and the m/z ratio of ions detected were summed across integral regions of 10 
ppm to allow for alterations in m/z mass accuracy across the experiment (“binning”). Ion intensities 
were normalised to total ion count, mean centred and Pareto scaled before production of single ion 
images or multivariate statistical analysis (PCA). During PCA, pixels can be considered analogous to 
“observations” and m/z values to “variables”. PC loadings were normalised according to their 
contribution to the overall variation prior to computing averages from different experiments. Multi-
ion image overlays were produced using ImageQuest software (Thermo Fisher Scientific).  
 
Univariate statistics: Unless stated otherwise, data is reported as mean value ± standard error of mean 
(SEM). Statistical significance was evaluated using ANOVA with Tukey’s post-hoc test. 
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Results 
Hepatic lipid signatures change with NAFL  
We induced NAFL in mice using dietary and genetic models: WT and ob/ob mice were maintained on 
a high fat (HF) or regular chow (RC) diet. WT (C57BL/6J strain) mice are susceptible to diet-induced 
obesity and develop NAFL when fed a HF diet (29), whilst ob/ob mice lack the ability to produce leptin, 
presenting a phenotype of obesity and insulin resistance, and spontaneously develop steatosis (29, 
30). Body weights for the four groups were measured after 12 weeks and found to increase in the 
order: WT-RC < WT-HF << ob/ob-RC < ob/ob-HF (31). NAFL was induced in the WT-HF and ob/ob mice, 
and was characterised by zone 3 macrovesicular steatosis, with the amount of steatosis greatest in 
the ob/ob-RC and ob/ob-HF groups (Figure 1A). Early signs of inflammation and cell injury were 
observed (Figure 1B), including increased liver enzymes and expression of pro-inflammatory cytokine 
Tnf- and pro-fibrotic factor Tgf-1.  
 
In order to determine whether the lipid signatures in liver tissue would enable the distinction of the 
groups above, we performed lipidomics experiments. Lipids were extracted from homogenised tissue 
and analysed by LC-MS. Overall in positive and negative ion modes, over 800 lipids were identified 
from 11 classes, including TAGs, diacylglycerides (DAG), phosphatidylcholines (PC), 
phosphatidylethanolamines (PE), phosphatidylinositols (PI), phosphatidylglycerols (PG), 
phosphatidylserines (PS), sphingomyelins (SM), cholesteryl esters and free fatty acids (FFA). As 
expected, the most striking observation was the relative increase in TAGs compared to PCs in NAFL 
liver compared to control (Figure 1C-1D). Identified lipids were used to construct a PCA model, which 
successfully discriminated the four sample groups (R2 = 0.93, Q2 = 0.90; Figure 1E). The first principal 
component related primarily to the disease status (NAFL or normal), whilst the second principal 
component differentiated the diets. The corresponding loadings plot (Figure 1F) revealed the lipid 
species most influential in distinguishing groups. These included a relative increase in PCs and 
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saturated fatty acids (SFA) for WT-RC control liver tissue; and a relative increase in TAGs and 
monounsaturated fatty acids (MUFA), particularly FFA(18:1), for the NAFL groups. The high fat diet 
groups had a greater proportion of polyunsaturated fatty acids (PUFA) and TAGs with longer chain 
length and greater unsaturation. In contrast, the ob/ob-RC group had the highest FFA(18:1) content 
of all four groups, and shorter chain TAGs. 
 
Next we carried out GC-MS to determine the total fatty acid profiles of liver tissue from the different 
groups, and to compare these with the profiles from the HF and RC feed (Figure S2, Table S4). 
Interestingly, the MUFA: SFA ratio was similar in the HF and RC diets, whilst increasing up to 4-fold in 
ob/ob-RC mice compared to WT-RC controls. This suggests that the increased hepatic MUFA is due to 
an increase in production through de novo lipogenesis (DNL) (4) and stearoyl co-A desaturase 1 (SCD1) 
activity. We calculated a proxy for increased SCD1 activity (32), and found this to be increased in ob/ob 
compared to WT mice, with the greatest increase observed in ob/ob-RC mice (Table S4). There was a 
high proportion of PUFAs in both diets, and consequently the HF-fed and WT-RC mice had similarly 
high PUFA content. The ob/ob-RC mice however had significantly lower PUFA compared to diet, 
presumably as a consequence of increased DNL and MUFA production. In summary, we have 
determined differences in both fatty acid content, and intact lipid species in liver tissue that are not 
attributable to diet alone, and are likely to arise from NAFLD or the metabolic context from which 
NAFLD arises.  
 
NAFL is associated with changes to lipid zonation 
Next we sought to address if lipids were differentially distributed in WT-RC control liver, and how such 
zonal patterns were affected with NAFL. Using MALDI-MSI, lipids were directly ablated from the 
surface of tissue, retaining spatial information that could be linked back to histology. Typically MALDI 
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spectra of liver tissue (Figure S1A) were composed primarily of potassiated PCs and their 
corresponding fragment ions (Table S5-S6). PCA was employed to comprehensively evaluate the 
spatial distribution of lipids in an unsupervised manner. PCA scores were visualised as a contour plot 
for each principal component. The first two principal components typically corresponded to 
histological features of interest with further components, representing successively less variation, 
attributed to artefacts of matrix deposition and tissue/matrix borders (Figure 2A, 2C). The loadings 
plot associated with each principal component represents the lipid species most important for 
discriminating regions (Figure 2B, 2D). For instance, SM(40:1) (m/z 825.622; [M+K+]) and PC(32:0) (m/z 
772.523; [M+K+]) were predominantly located in the central vein or portal vein, respectively (Figure 
2E). This was reflected in the scores and loadings plot for the first principal component. Zones 1 and 3 
could be distinguished based on their lipid profiles and subsequent PCA scores in the second principal 
component (Figure 2C-2D). In particular, PC(36:3) (m/z 822.538; [M+K+]) showed a strong zone 1 
distribution, whilst PC(34:2) (m/z 796.522; [M+K+]) was predominantly located in zone 3 (Figure 2E). 
Method reproducibility was assessed by comparing across serial sections from the same sample 
(Figure S3).  
 
We went on to compare the WT-RC liver tissue (Figure 3A) with tissue from NAFL groups with different 
extents of steatosis and inflammation (Figure 3B-3C). Using the PCA scores and loadings plots and 
cross-referencing to adjacent H&E stained sections (Figure 3), we identified lipids with strong and 
reproducible zone 1 or zone 3 distributions (Figure 3D-3E). Whilst PC(32:0) and SM(40:1) were 
typically the major lipids observed in portal vein and central vein, respectively, for all groups, changes 
were observed in the lipids located in zones 1 and 3 (Figure 3D-3E). For instance, PC(34:2) was 
distributed mainly in zone 3 in WT-RC and WT-HF mice (Figure 3A) but in zone 1 in ob/ob-HF (Figure 
3C, 3E). Of particular interest were AA-containing PC(38:4) (m/z 848.553; [M+K+]; fatty acid 
composition 18:0/20:4), which became more strongly localised in zone 3 for ob/ob mice, and 
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docosahexaenoic acid (DHA)-containing PC(38:6) (m/z 844.522; [M+K+]; 16:0/22:6) which shifted from 
zone 1 in WT mice to zone 3 in ob/ob mice (Figure 3D; Figure S4). This was mirrored to a certain extent 
by PC(40:7) (16:1/22:6) and PC(40:6) (16:0/22:6) (Figure 3D). 
 
NASH leads to further increase in monounsaturated fat and loss of zonation 
Having assessed the changes to lipid abundances and distributions in NAFL mice, we went on to 
similarly assess mouse models of NASH. Initially we sought to use the well-established methionine 
choline deficient (MCD) diet in mice to model NASH. We first assessed the hepatic lipid profile of MCD 
mice, compared to their methionine choline sufficient (MCS) controls by LC-MS (Figure S5). We were 
intrigued to note increased FFA(22:6) and long chain TAGs containing 22:6, whereas MUFAs were 
decreased or unchanged. Coupled with the knowledge that the MCD challenge induces weight loss, 
we interpret these results as a possible consequence of adipose tissue lipolysis (32, 33). We therefore 
opted for a Western diet (WD) to model NASH, since this can recapitulate the metabolic features of 
human NASH, whilst inducing obesity in mice (34-36).  
 
NASH was induced in WT mice by WD-feeding for 32 weeks. The WD contained high levels of 
cholesterol, sucrose and saturated fat. A low fat (LFD) diet, with similar total fatty acid profile (Table 
S4), was used as a control diet. After 12 weeks, the mice on WD developed macro- and microvesicular 
steatosis, in contrast to the mice on LFD (Figure 4A). After 32 weeks, mice on WD developed NASH, 
with characteristic pericentral fibrosis (Figure 4A), increased serum ALT and transcripts for Tnf- and 
Tgf-1 (Figure 4B).  
 
The hepatic lipid profile was measured by LC-MS for mice on WD and LFD at 12 and 32 weeks, and the 
identified lipids used to construct a PCA model (Figure 4C). Interestingly, the four groups were clearly 
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distinguished (R2 0.92, Q2 0.88). The most important lipids which distinguished the WD-32 week mice 
from the others were TAG(54:3) (18:1/18:1/18:1) and TAG(52:2) (16:0/18:1/18:1), highlighting the 
importance of increased 18:1 as a marker for both NAFL and NASH (Figure 4C). We confirmed the 
increased 18:1 by GC-MS, measuring total hepatic fatty acid profiles for all samples and their diets 
(Figure S2, Table S4). The MUFA: SFA and SCD1 ratio were substantially increased by WD feeding, with 
the highest levels determined for the 32-week WD mice (2-fold increase).   
 
Next we examined the zonal distribution of lipids in LFD and WD mice using MALDI-MSI (Figure 4D-
4F). Consistent with our earlier findings, PC(32:0) and SM(40:1) were associated with portal and 
central vein respectively. AA-containing lipids PC(36:4) and PC(38:4) were located primarily in zone 3 
for LFD and WD-12 week mice, whilst PC(34:1) and PC(32:1) were the major lipids in zone 1 (Figure 
4F). It was extremely difficult to build a statistical model for zonal differences in WD-32 week mice 
however, with zonal distributions for most lipids being relatively weak or absent (Figure 4E-4F). This 
is exemplified by SM(40:1), normally associated with central vein (Figure 4D), however becoming 
increasingly delocalised with disease progression.  
 
Lipid zonation in human NAFL and NASH 
Human liver samples, covering the spectrum of NAFLD from normal to cirrhotic (Figure 5A), were 
analysed by LC-MS to compared the overall lipid profiles (Figure S6). We were specifically interested 
in the differences between liver presenting NAFL compared to NASH (Figure 5B). Multivariate analysis 
of these two groups revealed that samples with NASH had increased FFA(18:1) and short chain TAGs, 
including TAG(52:2) (16:0/18:1/18:1), compared to samples with steatosis only. This was confirmed 
by GC-MS (Table S4), and an increase in SCD1 activity implicated in human NAFL and NASH, in excellent 
agreement with the mouse studies. 
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Next we performed MALDI-MSI, using adjacent H&E stained sections and principal components 
analysis to identify histological regions and quantify the zonation of lipids (Figure 5C). Similar to the 
mouse samples, the portal vein was characterised by PC(32:0), whilst SM(40:1) was found to be 
associated with both central and portal veins. Interestingly, there was little difference observed 
between the zonal distributions of lipids in normal and NAFL liver tissue. In both groups PC(34:2) and 
PC(36:4) were the most predominant lipids in zone 1, whereas PC(34:1) and PC(36:1) were strongly 
associated with zone 3 (Figure 5C-5D). With NAFL progression to NASH, however the differences 
between pericentral and periportal regions became less pronounced, with partial to complete loss of 
zonation (Figure 5C-5D). Cirrhotic liver was characterised by nodular and fibrotic regions, rather than 
the traditional lobular structure (Figure S7, Figure 5D). Areas of fibrosis were characterised by 
increased PC(32:0) and SM species, whereas nodules had increased PC(34:1) and PC(32:1) (Figure S7).  
 
Eicosanoid metabolism with NAFLD progression 
Eicosanoids and lipid mediators are fatty acid metabolites and have been implicated in the 
inflammation response, and in the progression of NAFL to NASH. We therefore extracted these 
metabolites from homogenised mouse and human liver tissue and analysed the extracts by LC-MS/MS 
(Figure S8, Table S3). Overall, we detected 34 different eicosanoids and lipid mediators including AA-
derived hydroxyeicosatetranoic acids (HETEs, 6), epoxyeicosatrienoic acids (EETs, 2), 
dihydroxyeicosatrienoic acids (DHETs, 3), prostaglandins (6); linoleic acid (LA)-derived 
hydroxyoctadecadienoic acids (HODEs, 2), epoxyoctadecaneoic acids (EpOMEs, 2), 
dihydroxyoctadecanoic acids (DiHOMEs, 2); eicosapentaenoic acid (EPA)-derived 
hydroxyeicosapentaenoic acids (HEPEs, 4) and DHA-derived hydroxydocosahexaenoic acids (HDoHEs, 
2).  
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The resulting hepatic eicosanoid profiles were used to construct OPLS-DA models to discriminate 
between WT-RC control and NAFL mice (WT-HF, ob/ob-RC, ob/ob-HF) (Figure S9). The most 
discriminating class of eicosanoids for control and NAFL liver were the HEPEs, HDoHEs, and HETEs 
(Figure S9D). In particular, n-3 DHA-derived 13-HDoHE and several n-3 EPA-derived HEPEs were 
significantly decreased in ob/ob mice and by HF-feeding (Figure 6A). In contrast, n-6 AA-derived 12-
and 15-HETE were significantly increased by HF-feeding alone, whilst 5- and 11-HETE were significantly 
increased in ob/ob mice and by HF-diet (Figure 6A). Next we assessed the eicosanoid profiles from the 
WD/LFD mice, finding decreased 13-HDoHE in WD-fed mice, however no significant differences were 
noted in HETEs (Figure 6B).  
 
We assessed similar metabolites in human liver, and determined that the concentrations of 9- and 13-
HODE, regulated by LOX and derived from n-6 fatty acid LA, were the most discriminating for NAFL 
and NASH, with both increased in NASH (Figure 6C), whilst there was no difference in 15-HETE 
concentration. Given that HETEs and HODEs are pro-inflammatory metabolites, we further examined 
how their levels were correlated with the pathologist-annotated “inflammation score”, finding 
increased levels with higher scores (p < 0.1 for 13-HODE and 15-HETE).   
 
Remodelling of phospholipid membrane feeds into upregulated eicosanoid synthesis 
AA is incorporated into the membrane by the action of acyl transferases, notably LPCAT2, whilst group 
IVA phospholipase A2 (cPLA2) preferentially cleaves PC to release free AA, which is then metabolised 
by LOX to form HETEs and other eicosanoids (Figure 7A). An increase in AA-derived HETEs can be 
therefore be explained by higher amounts of AA-containing intact lipid in the membrane, increased 
availability of free AA, increased activity of the LOX pathway, or a combination of the above. To 
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elucidate which of these pathways are upregulated in NAFL, we measured hepatic mRNA levels for 
Lpcat2, cPla2, Alox15 (15-LOX), Alox5 (5-LOX) and Alox12 (12-LOX) in WT-RC control and the three 
corresponding NAFL groups. A significant increase in hepatic mRNA levels for Lpcat2 and cPla2 was 
observed with NAFL in WT-HF, ob/ob-RC and ob/ob-HF mice, whereas Alox15 was significantly 
increased by high fat feeding only (Figure 7B). No change was noted for Alox12 or Alox5 across the 
groups.   
 
Hepatic transcript levels were measured for the mice fed WD or LFD for 12 and 32 weeks. Interestingly, 
there was a significant increase in Lpcat2 (4-fold) and cPla2 (3-fold) for the mice which developed 
NASH (32 weeks WD), whilst no change in Alox15 was observed across groups (Figure 7C). Similarly, 
hepatic mRNA levels for LPCAT2, cPLA2 and ALOX15 in human liver samples were measured (Figure 
7D). LPCAT2 and cPLA2 were increased by up to 3-fold in NASH compared to NAFL, whilst ALOX15 was 
significantly increased by up to 6-fold. It is worth noting that human 15-LOX prefers LA as a substrate 
producing 13-HODE, whereas the equivalent murine enzyme acts on AA to generate 15-HETE.  Overall 
despite differences, the agreement between mouse and human data is striking, and may suggest a 
conserved mechanism of NAFLD progression. 
 
Discussion 
Here we established the zonal distributions of phospholipids in liver with NAFLD progression, using 
mouse models of NAFL and NASH, and clinical samples covering a range of NAFLD severity. Overall, 
both similarities and differences were found between the mouse and human studies. Similar lipids 
were found associated with portal and central veins, whilst many of the periportal/pericentral 
zonation patterns were opposite. For instance, PC(34:2) and PC(36:4) are typically zone 3 in mice and 
zone 1 in humans; PC(34:1) is typically zone 1 in mice and zone 3 in humans. However, in both mouse 
and human NASH, there was a striking loss in lipid zonation.  
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Previous studies have shown knockouts of either Alox15 (37) or cPla2 (38, 39) in mice resulted in 
reduced steatosis and inflammation emphasizing the importance of these pathways in NAFLD. Our 
data provide evidence at the metabolite and gene expression level for remodelling of the hepatic PC 
component in NAFLD. Specifically, we show that the activities of LPCAT2, cPLA2 and 15-LOX are 
upregulated in NAFL and NASH. This results in a cycle of AA enrichment and release from the 
membrane, generation of pro-inflammatory eicosanoids, followed by reintroduction of AA into 
membrane phospholipids (Figure 7A). Our data further show transcript levels for LPCAT2 and cPLA2 
to be closely correlated in both the mice studies and the human study, suggesting that these two 
genes may be co-regulated (Figure 7E). Phospholipid remodelling in obesity has been linked to ER 
stress and disrupted calcium signalling (40). Given that the activities of both LPCAT2 and cPLA2 are 
calcium-dependent, further elucidation of the relationships between ER stress, calcium signalling and 
lipid remodelling in NAFLD may be warranted. 
 
Of particular interest in this study is LPCAT2, which reintroduces PUFA - notably AA, into the 
membrane. Using immunohistochemistry, we found higher staining for LPCAT2 protein in zone 1 for 
WT mice and in zone 3, particularly around regions of steatosis, for ob/ob mice (Figure 7F). The specific 
zonation of LPCAT2 protein, in addition to its increased gene expression, may account for the 
enrichment of AA-containing PCs in zone 3, which was noted in the MSI experiments for murine NAFL. 
In contrast, LPCAT2 protein is pericentrally located in normal and NAFL human liver (Figure 7F). Since 
AA-containing PCs are typically periportal in human liver, an enrichment of LPCAT2 and AA in zone 3 
would contribute to a loss of zonation for this lipid, which we observed in NASH. Whilst it is not clear 
whether the change in lipid zonation is a cause or effect of NAFLD, there does appear to be a link.  
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As a result of enrichment of AA in zone 3, generated eicosanoids will provide an inflammatory insult 
to hepatocytes in the pericentral region in particular. This may account for the increased oxidative 
damage observed in this region during NASH. Furthermore, since LPCAT2 is induced by pro-
inflammatory cytokines (41, 42) and is highly expressed in inflammatory cells such as macrophages 
and neutrophils (41), this could further reinforce the inflammation cascade. We stained for CD68-
positive cells (Kupffer cells, macrophages, monocytes; Figure S10) and found that these cells were 
distributed azonally in normal and NAFL human liver but in NASH were pericentrally located (also 
noted in (43)). Similarly, in human and murine NASH, LPCAT2 staining was highest surrounding 
pericentrally-located lipid droplets (Figure S11-S12) and inflammatory infiltrates. Taken together, this 
leads us to speculate that lipid droplet biology and macrophage infiltration may be important factors 
in the lipid remodelling observed during NAFLD.  
 
Overall this study has described the location of lipids and their associated metabolic pathways in NAFL 
and NASH. We provide a link between the upregulation of enzymes involved in membrane 
remodelling, fatty acid release, eicosanoid formation, and lipid composition, whilst suggesting areas 
of interest for future study. The integration of mass spectrometry imaging technology with 
computational tools and traditional biochemical techniques has been shown here as a powerful 
approach. Importantly, this has enabled the fatty acid content of intact phospholipids to be mapped 
to particular locations in tissue and presents the opportunity to follow changes to lipid composition 
and distribution with disease state.  
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Figure Legends 
Figure 1. Hepatic lipid signatures in murine NAFL. Increasing steatosis (WT-RC << WT-HF < ob/ob-RC 
 ob/ob-HF) was assessed by Masson’s trichrome staining (top; magnification x 200) and quantified 
(%) using oil red O lipid stain (bottom) (A). Serum alanine transaminase (ALT) was elevated in ob/ob-
RC and ob/ob-HF groups, and a stepwise increase in hepatic mRNA levels for Tnf-and Tgf-1 was 
observed in WT-HF, ob/ob-RC and ob/ob-HF groups; * p < 0.05, ** p < 0.01, *** p < 0.001 (B). 
Representative LC-MS chromatograms are shown for control (WT-RC) (C) and NAFL (ob/ob-HF) mouse 
liver (D). Lipids identified by LC-MS were used to construct principal components models (E), which 
clearly distinguish the four groups based on their lipid signatures. The associated loadings plot (F) 
shows the most important lipids for differentiating groups.  
Figure 2. Principal components analysis (PCA) of imaging data reveal liver histology. PCA analysis 
was employed to evaluate the spatial distribution of lipids, illustrated here for control (WT-RC) mouse 
liver tissue. The PCA scores for the first two principal components were plotted against x and y 
coordinates (yellow and blue colours indicate most positive and negative scores, respectively). This 
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gave rise to contour plots which here correspond to regional differences in central vein/portal vein 
(CV/PV) (A) and Zone 1/Zone 3 (C). The corresponding loadings plots (B and D) represent which lipids 
(m/z) are most important for differentiating regions. Two-dimensional single ion distributions for 
SM(40:1) [M+K+], PC(32:0) [M+K+], PC(36:3) [M+K+] and PC(34:2) [M+K+] show a central vein, portal 
vein, zone 1 or zone 3 distribution respectively (E). Highest intensities are shown in yellow. 
Figure 3. Lipid zonation in murine NAFL. Sections of mouse liver tissue were probed by MALDI-MSI or 
stained with H&E. Two-dimensional distributions for key ions (left) and PCA scores plots (right) closely 
recapitulate liver histology (middle). Key ion distributions show PC(36:3) [M+K+] (red), PC(34:2) [M+K+] 
(green), SM(40:1) [M+K+] (blue) for WT-RC control mice (A); PC(36:2) [M+K+] (red), PC(34:2) [M+K+] 
(green), PC(32:0) [M+K+] (blue) for WT-HF mice (B); PC(38:6) [M+K+] (red), PC(38:4) [M+K+] (green), 
PC(32:0) [M+K+] (blue) for ob/ob-HF mice (C). Positive and negative PCA scores are associated with 
zones 1 and 3, respectively (yellow and blue colours indicate most positive and negative scores, 
respectively). PCA loadings plots (far right) show the lipids of greatest importance for differentiating 
zones. Histological features of interest are labelled (PV = portal vein, CV = central vein, Z1 = zone 1, Z3 
= zone 3); m/z peaks labelled with asterisks are fragment ions. Zonation for different lipid species was 
quantified across biological replicates using PC loadings scores (D-E).  
Figure 4. Lipid changes in a mouse model of NASH. Masson’s trichrome staining (magnification x 100) 
reveals liver tissue from wild type (WT) mice on a Western diet (WD) for 12 weeks develop steatosis, 
and after 32 weeks develop NASH with fibrosis (stained blue; A). Serum ALT and hepatic transcripts 
Tnf- and Tgf-1 are elevated in 32 week WD mice compared to their low fat controls, and compared 
to 12 weeks WD (** p < 0.01, *** p < 0.001) (B).  PCA and corresponding loadings plot for distinguishing 
the groups based on their hepatic intact lipid profiles determined by LC-MS (C). Spatial distribution of 
SM(40:1) across liver tissue shows increasing delocalisation with disease progression. Highest intensity 
is shown in yellow (D). Lipid zonation becomes less marked in 32-week WD mice, as determined by PC 
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scores; yellow and blue represent most positive and negative scores, respectively (E). Quantification 
of the corresponding PC loadings show that lipid zonation is almost completely lost with NASH (F). 
Figure 5. Lipid distributions across the human NAFLD spectrum. H&E stained sections (magnification 
x 40) of human liver tissue ranging from normal, NAFL, NASH to cirrhosis (A). Homogenised liver tissue 
was analysed by LC-MS, and the lipidomic profile used to compare NAFL and NASH groups, revealing 
increased shorter chain TAGs, and FFA(18:1) in NASH (B). MALDI-imaging was performed on frozen 
sections of tissue, and quantified (C) revealing changes to zonation with NASH. Example MS images of 
tissue covering the spectrum of NAFLD are shown alongside corresponding adjacent H&E sections (D). 
Spatial distributions for PC(32:0) (portal vein), PC(36:4) and PC(34:1) are denoted as blue, red and 
green respectively for normal, NAFL and NASH. Greater intensity of colour reflects relative abundance. 
Whilst PC(36:4) and PC(34:1) are located in zones 1 and 3, respectively, in both normal and NAFL, 
there is partial to complete loss of zonation in NASH. Cirrhotic tissue on the other hand is marked by 
lipid changes to fibrotic and nodular regions (see supporting information). Spatial distributions for 
lipids denoted in blue, red and green for cirrhosis are PC(32:0), PC(34:1), PC(34:2), respectively.  
Figure 6. Changes to eicosanoid lipid mediators with NAFLD. Decreased n-3 fatty acid 
(eicosapentaenoic acid (EPA), DHA)-derived anti-inflammatory eicosanoids and increased n-6 fatty 
acid (AA)-derived pro-inflammatory eicosanoids observed in liver from ob/ob mice and mice on a high 
fat diet. Two way ANOVA was performed to assess the contribution of the diet, genotype (KO) and 
their interaction (~) to the metabolite changes observed (A). Similarly, a decrease in n-3 derived 13-
HDoHE was noted for mice following a Western diet, whilst no significant difference was determined 
for the n-6 derived HETEs (B). Significantly increased n-6 LA-derived pro-inflammatory HODEs were 
observed in liver with NASH, compared to NAFL, in human liver tissue. Increased HETEs and HODEs (p 
< 0.1) were found in human samples with a higher inflammation score (C). Data are expressed as 
median ± upper/lower quartile (* p < 0.05, ** p < 0.01, *** p < 0.001). 
27 
 
27 
 
Figure 7. Fatty acid remodelling in NAFLD. Group IVA phospholipase (cPLA2) preferentially cleaves 
phosphatidylcholine (PC) to release arachidonic acid (AA). AA can then be metabolised by 
lipoxygenases (LOX) to form eicosanoids, including pro-inflammatory HETEs. PCs are regenerated by 
the action of lysophosphatidycholine acyl transferases (LPCAT) on lysophosphatidylcholines (LysoPC) 
(A). An increase was observed in hepatic mRNA levels for cPla2 and Lpcat2 with high fat (HF) diet and 
for ob/ob mice (two way ANOVA). Alox15 was significantly increased by HF-feeding only (B). Gene 
transcripts for cPla2 and Lpcat2 were significantly increased in mice fed a Western diet (WD) for 32 
weeks (C). Similarly, hepatic mRNA levels for cPLA2, LPCAT2 and ALOX15 were all increased in human 
NASH compared to NAFL; * p < 0.05, ** p < 0.01, *** p < 0.001 (D). A striking correlation between 
Lpcat2 and cPLa2 mRNA levels were noted in both mouse and human studies (E). Immunostaining 
(magnification x 50) showed that LPCAT2 protein has a distinct periportal distribution in WT mice, and 
a pericentral distribution in ob/ob mice and human liver (F).  
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